(Photo Courtesy: www.newsatjama.jama.com)
In September 2014, Strides entered into a licensing agreement with Gilead Sciences, to bring hepatitis C cure to 91 developing countries.
The product will be available to Indian patients shortly.
Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for hepatitis C treatment and represents a paradigm shift in the existing hepatitis C management.
The high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of Sofosbuvir makes it a breakthrough drug in hepatitis C treatment.
This drug in combination therapy has shown to have high cure rates of around 90 percent.